Fly News Breaks for February 5, 2020
Feb 5, 2020 | 06:21 EDT
JMP Securities analyst Liisa Bayko upgraded Arbutus Biopharma to Outperform from Market Perform with a $10 price target. The analyst sees a favorable risk-reward on the stock going into its first in-human data of AB-729 in late Q1 and believes that the drug can be competitive with the best-in-class ARO-HBV, helping the company advance its goal to create a functional cure for HBV. Bayko adds that Arbutus Biopharma represents a "great opportunity" for investment with shares trading just above cash value.
News For ABUS From the Last 2 Days
There are no results for your query ABUS